Max S. Topp, MD, discusses the efficacy of the combination of glofitamab plus R-CHOP from a phase 1 trial done in previously untreated patients with diffuse large B-cell lymphoma.
Max S. Topp, MD, head of the Department of Hematology, University Hospital of Würzburg, in Würzburg, Germany, discusses the efficacy of the combination of glofitamab plus R-CHOP (rituximab [Rituxan], cyclophosphamide, doxorubicin, vincristine, and prednisone) from a phase 1 trial (NCT03467373) done in previously untreated patients with diffuse large B-cell lymphoma (DLBCL).
Data from both the safety run-in portion and the expansion stage of the study were presented at the 2022 ASH Annual Meeting. All agents that comprised the R-CHOP regimen were administered at a categorized dose intensity of at least 90% in more than 90% of patients, except for vincristine, which was received at a dose intensity of at least 90% in 62.5% of patients, Topp notes.
Among 56 evaluable patients with DLBCL, the 53 who were exposed to glofitamab comprised the efficacy population, Topp adds. The combination elicited an overall response rate of 86.8% and a complete metabolic response rate of 75.5% in this population, Topp concludes.